Tumors with low- and ultra-low levels of a protein called HER2 are treatable with Enhertu, but harder to identify. New ...

In an AstraZeneca-developed training program, AI-assisted HER2 IHC scores had higher agreement with centrally confirmed scores.

AI-assisted training notably improved pathologist accuracy in HER2-low breast cancer, reducing misclassification and ...

Assistance from artificial intelligence can potenially increase the number of patients eligible for treatment for HER2-low ...

Traditionally, HER2 status has been determined by immunohistochemistry (IHC) and in situ hybridization (ISH), distinguishing ...

Each year, millions of women undergo mammography to screen for breast cancer, yet tiny calcium specks—known as microcalcifications—often evade detection or are misread, leading to delayed diagnoses or ...